ArticleOncology letters2012
Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.BMC cancer · 2017Pooled it
- Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.Oncotarget · 2017Pooled it
- Significance of Circulating Cell-Free DNA Biomarkers in HBeAg-Negative Chronic Hepatitis B Virus Infection and Their Changes after Treatment Initiation.Pathogens (Basel, Switzerland) · 2023Article
- Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring.Oncology research · 2023Review
- Quantitative analysis of serum cell-free DNA as a predictive and prognostic marker in breast cancer patients.Frontiers in oncology · 2023Article
- Circulating Cell Free DNA and DNA Integrity Index as Discriminating Tools between Breast Cancer and Benign Breast Disease.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- The Significance of Circulating Cell-Free DNA Markers in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.Pathogens (Basel, Switzerland) · 2021Article
- The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.British journal of cancer · 2021Review
- Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine.Cancers · 2021Review
- Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.Cancer genetics · 2018Review
- Microfluidic-based solid phase extraction of cell free DNA.Lab on a chip · 2018Article
- Quantitation of cell-free DNA in blood is a potential screening and diagnostic maker of breast cancer: a meta-analysis.Oncotarget · 2017Article
- Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.Breast cancer research and treatment · 2015Observational
- Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Expert review of molecular diagnostics · 2015Review
- Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.Journal of cancer research and clinical oncology · 2013Article
- An exposure to the oxidized DNA enhances both instability of genome and survival in cancer cells.PloS one · 2013Article
- Integrity and Quantity Evaluation of Plasma Cell-Free DNA in Triple Negative Breast Cancer.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a highly malignant disease in women. A convenient screening tool with high accuracy for early detection, not only in high-risk individuals but in the general population, is necessary. Two hundred breast cancer patients, 100 healthy controls and 100 hyperplasia patients were enrolled in this study. Samples were randomly assigned into training or testing cohorts. The receiver operating characteristic curve was used to explore the optimal concentration of cell-free DNA (GAPDH) in the training cohort and the cut-off point was validated in the testing cohort. The results showed that both in the training and testing cohorts, the overall accuracy of classification between cancer, healthy controls and hyperplasia was higher than 0.9. The sensitivity, specificity, positive predictive value and negative predictive value also reached 0.9, with the exception of the negative predictive value in the testing cohort. This study provides useful information on the use of concentration of free DNA for breast cancer detection. These findings need to be validated in a large prospective trial prior to clinical application.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.